Successfully creates transgenic based on underwater adhesive properties of Caddisfly

ANN ARBOR, Mich., – February 10, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, proudly announces the successful creation of new novel silk, build upon the silk proteins of the remarkable caddisfly. This breakthrough marks a new frontier in the field of engineered fibers and underscores the Company’s commitment to pioneering innovations in biotechnology.

Caddisflies (known in the Pacific Northwest as “Periwinkles”) are known for their extraordinary ability to spin silk underwater, which they use to construct protective cases in aquatic environments. By leveraging the unique mechanical and chemical attributes of caddisfly silk proteins, Kraig Labs seeks to engineer materials with unprecedented functionality. This new silk offers the potential for increased durability when submerged in water. Possible applications for this new silk are vast, with exciting potentials for medical adhesives, biomedical textiles, performance apparel, and next-generation fiber technologies.

“This achievement demonstrates our ability to extend beyond spider silk proteins and explore the broader possibilities of silk engineering,” said CEO and Founder of Kraig Labs, Kim Thompson. “By tapping into the evolutionary diversity of silk-producing organisms, we’re expanding the toolkit for creating super fibers that meet the demands of tomorrow’s industries.” 

The introduction of caddisfly-based transgenic fiber represents a critical milestone in the Company’s vision to create new super materials blending the physical and chemical properties of various silk proteins. The result is an ever-growing portfolio of high-performance materials designed to redefine the standards of strength, elasticity, and functionality.  These new fibers will leverage the Company’s propriety silkworm-based production system to bring these materials to market.

“Incorporating the unique and incredible adhesive properties of caddisfly silk protein has been a key part of the R&D roadmap I laid out when founding Kraig Labs,” Thompson continued. “Unveiling this pivotal scientific milestone, our first caddisfly-based transgenic, marks not only a significant leap forward for the Company’s business model but also a deeply gratifying achievement for me personally and for our team.”

This breakthrough would not have been possible without the dedication and ingenuity of the Company’s scientific team. Their relentless pursuit of excellence and creative problem-solving have once again positioned Kraig Labs at the forefront of biotechnological innovation.

“Our team’s success with this caddisfly-inspired material is a testament to the power of combining cutting-edge science with bold vision,” added the Company’s COO, Jon Rice. “We are excited about the potential this fiber holds and the new opportunities it creates across multiple sectors.”

Kraig Labs is committed to pushing the boundaries of creativity and science in silk protein engineering. The Company has filed a provisional utility patent application for this exciting new technology. By exploring and integrating the diverse properties of silk from various species, the Company will continue to lead the charge in developing sustainable, high-performance materials that address real-world challenges.

For details about other recent advancements that Kraig Labs has made, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 23, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, proudly announces that it has received a new investment license in Vietnam. This strategic authorization marks a significant milestone in the Company’s mission to expand its production operations to meet the growing demand for its high-performance spider silk materials.

The newly acquired investment license empowers Kraig Labs to scale its production operations significantly and begin addressing the growing requests for materials and requests for quote that it has been fielding. This expansion will bolster the Company’s ability to provide its innovative materials to a broad spectrum of markets, including textiles, defense, and medical sectors, eagerly anticipating these breakthrough fibers’ commercial availability.

“We are thrilled to secure this new investment license in Vietnam. This license is a testament to our commitment to expanding our production capabilities and the confidence the team placed in our technology,” said Founder and CEO of Kraig Labs, Kim Thompson. “This license positions us to grow our production footprint and fulfill the increasing demand for materials. This expansion is moving us forward with our vision for cost-effective spider silk production become a reality.”

The Company’s expansion plans in Vietnam include developing advanced rearing facilities and increasing the production of its advanced materials. The Company remains committed to environmentally sustainable practices, leveraging its biotech innovations to deliver materials that are strong, lightweight, and eco-friendly.

This development aligns with Kraig Labs’ vision to revolutionize material science by bringing to market one of the most sought-after and impactful biomaterials of the 21st century.

For details about other recent advancements the Company has made, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 21, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, announces that it has secured $10 million in a standby equity purchase agreement (“SEPA”) with YA II PN, Ltd. (“Yorkville”). This agreement will provide the Company with access to the working capital necessary to continue production expansion for its revolutionary recombinant spider silk fibers and materials. 

Kraig Labs structured the SEPA to allow the Company to access capital over the next 36 months, when and how it determines best for the growth of spider silk production and end-market development. The Company is under no obligation to utilize this funding, has no minimum use requirements, and it does not impose any restrictions on the Company’s operations. This agreement gives the Company the flexibility to access the capital necessary to bridge its transition to revenue generation.

“We have worked with Yorkville in the past and we are excited to renew and strengthen that relationship. This strategic financial relationship provides Kraig Labs with the flexibility to support the growth of spider silk commercialization,” said Founder and CEO, Kim Thompson. “The SEPA provides access to significant growth capital, allowing us to focus on executing our vision for eco-friendly, cost-effective spider silk production. We will put this capital to work, building out our production capacity and spider silk inventory, developing new consumer products, and establishing partnerships with market channel sales partners.”

For details about other recent advancements the Company has made, please see the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 7, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, is happy to announce the successful creation of a new transgenic, inspired by the Darwin’s bark spider (Caerostris darwini). This milestone represents a significant leap forward in the production of high-performance recombinant spider silk, setting the stage for a new benchmark for strength and toughness in engineered materials.

Darwin’s bark spider silk has been documented by some studies as the toughest biological material ever measured, over 10 times tougher than para-aramid fibers, the material used in bulletproof vests and other high-strength applications. Drawing upon these insights, Kraig Labs has successfully incorporated key genetic elements of this remarkable silk into its proprietary transgenic silkworms to create a scalable production system for this amazing material.

“This breakthrough underscores our commitment to pioneering cutting-edge materials inspired by nature’s most extraordinary designs,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “By leveraging the unique properties of Darwin’s bark spider silk, we are advancing the boundaries of what’s possible in biomaterial science and bringing us closer to commercial-scale production of ultra-high-performance fibers.”

The Company’s research team has integrated key genetic sequences derived from Darwin’s bark spider silk proteins into silkworms. This process combines the strength and elasticity of the Darwin’s bark spider silk with the efficiency of traditional silkworm silk production. This new transgenic marks the next in a series of transformative materials that Kraig Labs is developing for the textile, defense, medical, and industrial sectors.

“We recently reported that our molecular biology team was firing on all cylinders. Today’s announcement is a public disclosure of just one of the many breakthroughs that they recently achieved,” said COO of Kraig Labs, Jon Rice. “I expect that 2025 will be a year filled with many new and exciting developments from our labs while our production team delivers metric ton production of our existing hybrids.”

The Company sees this breakthrough as further reinforcement of its leading position in sustainable spider silk-based supermaterials. The Company’s transgenic silk technology not only opens the door for new commercial applications but also represents a significant step towards reducing environmental impacts in textile manufacturing.

For details about other recent advancements the Company has made, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

As the year comes to a close and the holiday season wraps us in its warmth, we at Kraig Biocraft Laboratories want to take a moment to reflect on 2024—a year that will be remembered as a true turning point in our journey.

This year, we achieved what many thought impossible: the successful transition from innovation to production, unlocking the full potential of spider silk as a game-changing material. The introduction of our BAM-1 production hybrids was nothing short of transformative, propelling us into large-scale, sustainable spider silk manufacturing for the very first time.

In 2024, we produced over 1,200 pounds of recombinant spider silk cocoons—more material than we generated in all previous years combined. In fact, the last six months alone marked an incredible surge in production, with BAM-1 hybrids doubling cocoon size and silk yield. Each cycle brought stronger, healthier silkworms, bigger cocoons, and better results. As we enter this holiday season and reflect on the year behind us, I am filled with a sense of profound joy as we share these accomplishments together.

What we achieved this year is more than just numbers—it’s proof that perseverance, innovation, and teamwork can move mountains. It’s the culmination of years of dedication, and yet it feels like only the beginning. In 2025, we anticipate producing multiple tons of finished spider silk yarn, and firmly establishing Kraig Labs as the world leader in recombinant spider silk.

Beyond production, we’ve laid the groundwork for commercialization. We are entering 2025 ready to introduce our first offerings in luxury fashion and performance textiles, markets that are hungry for innovation and differentiation. The opportunity ahead is immense, and we couldn’t be more excited to see spider silk woven into products that inspire, protect, and perform.

On the science front, our molecular biology team delivered outstanding progress, creating advanced transgenic silkworm strains producing new fibers that the world has never seen before. We’ve had a series of significant breakthroughs in the lab under the leadership of our new head of molecular biology here at Kraig Labs. I look forward to introducing her to you, our shareholders and unveiling the new transgenics our team has created over these last few months. These developments are paving the way for even stronger, more versatile materials, ensuring that our leadership in spider silk technology will endure well into the future.

2024 was a year of breakthroughs, of milestones reached, and records set. We’re proud of what we’ve accomplished, but most importantly, we’re grateful—for our team, our partners, and for you, our loyal shareholders and supporters. Without your belief in our vision and your patience through every challenge we’ve overcome, none of this would be possible.

As we look to 2025, we do so with renewed energy and excitement for what lies ahead. We’ve proven that spider silk is no longer just a marvel of nature—it’s a reality we’re bringing to the world. Together, we are building something extraordinary.

From all of us at Kraig Labs, we wish you a joyful holiday season filled with love, laughter, and the company of those you hold dear. May the New Year bring you happiness, health, and success.

Thank you for standing with us. The best is yet to come.

Season’s Greetings, Happy New Year, Merry Christmas, and Happy Hanukkah to all our shareholders and the world.

Kim Thompson and the Kraig Labs’ Family

World’s First Commercially Viable Silkworms for Recombinant Spider Silk Production

ANN ARBOR, Mich., – December 16, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, reflects on a year of extraordinary progress following the introduction of its groundbreaking BAM-1 hybrids—the world’s first commercially viable silkworms recombinant spider silk production.

Since their debut earlier this year, the BAM-1 hybrids have proven to be a transformative innovation, driving significant advancements in silk production, cocoon size, yield, and silkworm robustness. These achievements validate the Company’s pioneering technology and its potential to revolutionize biomaterial manufacturing.

Over the past year, the BAM-1 hybrids have delivered remarkable results, including a doubling of cocoon size compared to traditional silkworms. This dramatic increase has directly translated to significantly higher silk yields, establishing new performance standards for productivity and efficiency in spider silk production.

In addition to improved yields, BAM-1 hybrids have demonstrated exceptional robustness and resilience. Their enhanced performance has been instrumental in advancing the scalability and consistency required for large-scale commercial operations, resulting in more than 1,200 pounds of recombinant spider silk cocoon production this year.

The BAM-1 hybrids are the world’s first silkworm for commercially viable recombinant spider silk production. By achieving reliable and repeatable yields at scale, Kraig Labs has set a new industry benchmark and opened the door to a wide range of applications, including technical textiles, defense, medical devices, and performance apparel.

“The introduction of the BAM-1 hybrid earlier this year marked a turning point for Kraig Biocraft Laboratories and for the future of spider silk production,” said Kim Thompson, CEO and Founder of Kraig Labs. “The extraordinary gains in cocoon size, silk yield, and silkworm resilience have validated our technology and enabled us to take significant steps toward industrial-scale production. This year has been about transforming promise into progress, and we are proud of what we have accomplished with BAM-1. Next year, we will expand on this success with production planning underway for multiple tons of spider silk production in 2025.”

The Company’s ongoing innovations and achievements in 2024 position Kraig Labs as a global leader in sustainable, high-performance spider silk production, unlocking new possibilities in biomaterials.

For more details about this breakthrough and other advancements the Company has made this year, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Milestone Surpasses All Previous Year’s Combined Production, Signifying Major Breakthrough in Commercialization Efforts

ANN ARBOR, Mich., – December 11, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, reports that it has produced more than 1,200 pounds of recombinant spider silk cocoon over the last 12 months. This milestone represents more than the combined production of all prior years, underscoring the Company’s significant advancements in scaling up spider silk production for commercial applications.

The successful production surge was driven by Kraig Labs’ newest hybrid spider silk production strain, which transformed traditional silkworms into producers of spider silk-based fibers. This record output demonstrates the Company’s ability to bridge the gap between laboratory innovation and scalable, sustainable production.

“We are proud to share this exciting production milestone. This achievement is a clear indicator of the tremendous progress our team has made in optimizing spider silk production,” said Kim Thompson, Founder and CEO of Kraig Labs. “This achievement puts us on track to begin addressing the global demand for performance fibers across a range of consumer end markets.”

Kraig Labs’ focus on building a reliable and scalable production model has positioned the Company as a leader in recombinant spider silk manufacturing. This accomplishment sets the stage for expanded production capacity and accelerated commercialization of its eco-friendly and high-performance silk fibers.

For more details about this breakthrough and other advancements the Company has made this year please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Investor Web Conference Transcript

ANN ARBOR, Mich., – December 3, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, today announced it will be publishing its investor web conference on December 4, at 4:30 pm ET. This conference provides an in-depth review of the Company’s amazing progress over the past twelve months in commercializing its revolutionary spider silk fibers.

“This has been an amazing year for Kraig Labs and for commercial scale production of recombinant spider silk for the textile markets. I am excited to share the record-setting progress Kraig Labs made this year in scaling up our spider silk production and in the development of the next generation of super fibers,” said Company Founder and CEO, Kim Thompson. “This shareholder conference will highlight the substantial business model progress we have made this year, as well as some of our upcoming targets and goals.”

Interested viewers will be able to find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270 starting on December 4, at 4:30 pm ET. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, MI., – November 4, 2024-  Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of advanced spider silk-based fibers, is pleased to announce the successful completion of its fourth production cycle for 2024. This achievement marks a significant milestone, with record-setting performance across nearly every tracked metric for parental silkworm lines and hybrid cocoons.

The latest production cycle delivered the largest single batch of parental line cocoons the Company has ever produced. On top of the record-setting size of this batch, Kraig Labs continues to see strong vitality and robustness.

Beyond the sheer size of this production batch, quantitative analysis of this batch demonstrated that the genetics of the BAM-1 continue to improve. This batch set new records for cocoon size, shell weight, and several other key metrics for large-scale production. These records were set not only our hybrid cocoons, but also for the parental silkworm lines, reflecting comprehensive improvements throughout the entire production process.

“The results of our fourth production cycle are outstanding, showcasing the performance and capability of our BAM-1 line,” said founder and CEO of Kraig Labs, Kim Thompson. “Our ongoing advancements in genetic engineering and silkworm rearing techniques are paying off, and these achievements underscore our ability to reliably scale up production to meet growing market demands.”

By achieving new records in both parental and hybrid silkworm metrics, the Company solidifies its leadership in the field of sustainable, high-performance fibers.

“The continuous improvement in nearly every tracked performance metric is a testament to the dedication and expertise of our team and the genetics of BAM-1,” said the Company’s COO, Jon Rice. “Our comprehensive focus on genetic robustness and cocoon yield has paid off. We are well on track for scaling our operations to multi-ton levels while maintaining the quality and performance of our spider silk materials.”

Kraig Biocraft Laboratories continues to pursue new heights in advanced biomaterials, driving innovation and setting new standards in the production of spider silk fibers.

The Company will hold an investor conference call later this month at a time to be announced in the coming weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com